| Tang, Yong |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 3 | 663 | RoW | Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel | Shanghai Junshi Bioscience Co., Ltd. | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 05/27 | 05/27 | | |
| Wang, Xia |
NCT03366883: Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC |
|
|
| Not yet recruiting | 3 | 420 | RoW | Paclitaxel, Cisplatin Plus 5-FU (TCF), radiochemotherapy | Tianjin Medical University Cancer Institute and Hospital, Shanghai Chest Hospital, Henan Cancer Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University | Esophageal Cancer Stage IIB, Esophageal Cancer Stage III | 02/18 | 12/22 | | |
NCT05354843: SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 37 | RoW | ET0038 | Etern BioPharma (Shanghai) Co., Ltd | Advanced Solid Tumor | 10/23 | 10/25 | | |
AMS-AF, NCT05316870: Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation |
|
|
| Recruiting | N/A | 380 | RoW | Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions, Conventional general practitioner management model | Beijing Municipal Health Commission, Exhibition Road Community Health Service Center of Xicheng District, Beijing, China, Xinjiekou Community Health Service Center of Xicheng District, Beijing, China, Guanwai Community Health Service Center of Xicheng District, Beijing, China, Guannei Community Health Service Center of Xicheng District, Beijing, China | Atrial Fibrillation | 12/22 | 12/22 | | |
NCT04212494: Thrombus Aspiration in STEMI Patients With High Thrombus Burden |
|
|
| Recruiting | N/A | 3838 | RoW | Thrombus aspiration, PCI Alone | Guangdong Provincial People's Hospital, Zhongshan People's Hospital, Guangdong, China, Kaiping Central Hospital, The Second Affiliated Hospital of Shantou University Medical College, The Third Xiangya Hospital of Central South University, Sihui City People's Hospital, Shenzhen Baoan District Shiyan People's Hospital, People's Hospital of Nanxiong County, Yuebei People's Hospital, Weifang Medical University, Wuzhou Gongren Hospital, Dafeng Hospital of Chaoyang District in Shantou City, Shenzhen Baoan People's Hospital, Dongguan People's Hospital, Yangchun People's Hospital, Taishan People's Hospital, The Second People's Hospital of Foshan, Guangzhou Hospital of integrated Traditional and West Medicine, Guangning People's Hospital, Foshan Sanshui District People's Hospital, Qingyuan People's Hospital, Luhe County People's Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The Fourth People's Hospital of Chenzhou, People's Hospital of Dapu County, Shenzhen People's Hospital, Heyuan people's Hospital, Huaiji People's Hospital, People's Hospital of Yingde City, Qingyuan Hospital of Traditional Chinese Medicine Affiliated To Guangzhou University of Traditional Chinese Medicine, Zhongshan Hospital Of Traditional Chinese Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Lianzhou People's Hospital, Lianping Xian Ren Ming Yi Yuan, Guangxi Zhuang Autonomous Region Nationalities Hospital, Liuzhou Municipal Liutie Central Hospital, Chen Zhou 3RD People's Hospital, Longgang District Central Hospital of Shenzhen, The Affiliated Shunde Hospital of Jinan University, Shenzhen Longhua District Central Hospital, Shantou Central Hospital, Tongxiang First People's Hospital, Bobai County People's Hospital, Guangxi, Meizhou Traditional Chinese Medicine Hospital, The Third Affiliated Hospital of Sun Yat-Sen University, Yuedong Hospital, Shenzhen Third People's Hospital, Yangjiang People's Hospital, Jiangmen Central Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, The First People's Hospital of Kashgar Erea, First People's Hospital of Foshan, Zhaoqing Gaoyao People's Hospital, People's Hospital of Nanhai District, Foshan, The Second Affiliated Hospital of Dalian Medical University, Nanning Second People's Hospital, The Second People's Hospital of Nanhai District of Foshan, Shangyou People's Hospital | ST-segment Elevation Myocardial Infarction (STEMI) | 08/25 | 02/26 | | |
NCT05484895: Mobile Health Intervention to Increase HIV Testing and Linkage to Care |
|
|
| Active, not recruiting | N/A | 1800 | RoW | WeTest-WeLink, Control condition | Emory University, Anhui Medical University, Rutgers University, University of Arkansas, National Institute of Mental Health (NIMH) | HIV | 01/25 | 01/25 | | |
| Ba, Yi |
NCT03366883: Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC |
|
|
| Not yet recruiting | 3 | 420 | RoW | Paclitaxel, Cisplatin Plus 5-FU (TCF), radiochemotherapy | Tianjin Medical University Cancer Institute and Hospital, Shanghai Chest Hospital, Henan Cancer Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University | Esophageal Cancer Stage IIB, Esophageal Cancer Stage III | 02/18 | 12/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
HLX10-006-GCneo, NCT04139135: A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 3 | 642 | RoW | HLX10, Recombinant humanized anti-PD-1 monoclonal antibody injection, Placebos | Shanghai Henlius Biotech | Gastric Cancer | 10/23 | 10/24 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT04555304: Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy |
|
|
| Not yet recruiting | 2 | 81 | NA | KH903 + Paclitaxel, Placebo + Paclitaxel | Chengdu Kanghong Biotech Co., Ltd. | Gastric Cancer, Gastroesophageal Cancer | 01/22 | 01/22 | | |
NCT05035381: PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 10 | RoW | Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen, Bevacizumab, Irinotecan, Fluorouracil, Leucovorin | Tianjin Medical University Cancer Institute and Hospital | MSI-H Advanced Colorectal Cancer | 12/22 | 12/22 | | |
NCT04969029: Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations |
|
|
| Recruiting | 2 | 30 | RoW | Tirelizumab | Tianjin Medical University Cancer Institute and Hospital | Immunotherapy, Adjuvant Therapy, Colon Cancer, MSI-H | 12/23 | 12/24 | | |
NCT06383559: Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients |
|
|
| Recruiting | 2 | 39 | RoW | Lenvatinib and Sintilimab | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 07/26 | 09/26 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT06430827: Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma |
|
|
| Not yet recruiting | 2 | 20 | RoW | irinotecan hydrochloride liposome injection, duoenyi, Capecitabine, Kapeitabin | Ba Yi, CSPC Ouyi Pharmaceutical Co., Ltd. | Biliary Tract Carcinoma | 12/24 | 12/25 | | |
TOBACO, NCT05077839: Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC |
|
|
| Recruiting | 2 | 184 | RoW | Trifluridine/Tipiracil, TAS-102 | Tianjin Medical University Cancer Institute and Hospital | First-line Treatment, Advanced Colorectal Cancer | 08/24 | 08/25 | | |
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gastroesophageal Adenocarcinoma | 09/26 | 09/27 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT04229537: Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC |
|
|
| Not yet recruiting | 1 | 60 | NA | SCT-I10A, SCT200, Chemotherapy | Sinocelltech Ltd. | Esophageal Squamous Cell Carcinoma, Colorectal Cancer | 08/22 | 12/22 | | |
NCT05388279: A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors |
|
|
| Terminated | 1 | 3 | RoW | JS012, JS012 combine with chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Advanced or Metastatic Solid Tumors | 09/22 | 09/22 | | |
NCT04190823: A Study of RC98 in Subjects With Advanced Malignant Solid Tumors |
|
|
| Active, not recruiting | 1 | 63 | RoW | RC98, RC98 for Injection | RemeGen Co., Ltd. | Solid Tumors | 12/23 | 12/23 | | |
| Recruiting | 1 | 96 | RoW | TQB3454 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor or Hematologic Tumor | 12/22 | 12/22 | | |
NCT05221775: Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients |
|
|
| Recruiting | 1 | 18 | RoW | Lenvatinib | Tianjin Medical University Cancer Institute and Hospital | First-line Treatment, Advanced Gastric Carcinoma | 03/23 | 10/23 | | |
NCT05514158: To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) |
|
|
| Recruiting | 1 | 24 | RoW | RC48-ADC, RC48-ADC injection, RC98, RC98 injection | RemeGen Co., Ltd. | Gastric Cancer | 05/24 | 09/24 | | |
NCT05367635: A Study of SKB315 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 206 | RoW | SKB315 for injection | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Advanced Solid Tumors | 05/24 | 05/24 | | |
| Not yet recruiting | 1 | 96 | RoW | KM501 | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/26 | 12/27 | | |
| Huang, dingzhi |
ACROSS1, NCT04500704: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC |
|
|
| Not yet recruiting | 3 | 166 | RoW | Almonertinib, Ameile, Almonertinib plus carboplatin and pemetrexed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Non Small Cell Lung Cancer | 12/21 | 10/23 | | |
SAINT, NCT04797806: Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC |
|
|
| Recruiting | 3 | 206 | RoW | Anlotinib, Icotinib | Tianjin Medical University Cancer Institute and Hospital | Non Small Cell Lung Cancer | 04/22 | 04/23 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
TQB2450-III-12, NCT05718167: TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. |
|
|
| Not yet recruiting | 3 | 570 | RoW | TQB2450, Anlotinib hydrochloride capsule, Tislelizumab injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Squamous Non-Small Cell Lung Carcinoma | 10/24 | 10/25 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. |
|
|
| Recruiting | 3 | 518 | RoW | TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non-small Cell Lung Cancer | 08/25 | 12/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
HS-20117 301, NCT06417008: A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2/3 | 1080 | NA | HS-20117, PM1080, Aumolertinib, Almonertinib Mesilate Tablets, HS-10296, Almonertinib | Hansoh BioMedical R&D Company | Non-Squamous Non-Small Cell Lung Cancer | 06/26 | 06/30 | | |
| Recruiting | 2 | 82 | RoW | Pembrolizumab Injection [Keytruda] | Tianjin Medical University Cancer Institute and Hospital | ESCC, Adjuvant Treatment, Lymph Node Positive, Pembrolizumab | 04/22 | 04/24 | | |
AUTUMN, NCT04553887: Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial |
|
|
| Not yet recruiting | 2 | 53 | RoW | Almonertinib | Tianjin Medical University Cancer Institute and Hospital | Non Small Cell Lung Cancer | 05/23 | 05/23 | | |
ARISE, NCT04354961: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 13 | RoW | Almonertinib, Investigational Product | Fujian Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Pulmonary Adenosquamous Carcinoma | 12/23 | 06/25 | | |
NCT06143735: A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors |
|
|
| Not yet recruiting | 2 | 99 | RoW | Efgbemalenograstim alfa | Tianjin Medical University Cancer Institute and Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 12/24 | 06/26 | | |
| Recruiting | 2 | 270 | RoW | TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | 10/25 | 02/26 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT05435274: Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 380 | RoW | HS-10376 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Advanced Non-Small-Cell Lung Cancer | 10/24 | 10/25 | | |
NCT05991349: A Study of IBI129 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 180 | RoW | IBI129 | Innovent Biologics (Suzhou) Co. Ltd. | Solid Tumor | 11/24 | 05/25 | | |
NCT04882033: Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 9 | RoW | Concurrent chemoradiotherapy plus anlotinib | Tianjin Medical University Cancer Institute and Hospital | Small Cell Lung Cancer Limited Stage | 07/21 | 07/23 | | |
NCT05507593: Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 18 | RoW | DLL3-CAR-NK cells | Tianjin Medical University Cancer Institute and Hospital | SCLC, Extensive Stage | 03/23 | 07/23 | | |
NCT05315180: A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 80 | RoW | BPI-421286 | Betta Pharmaceuticals Co., Ltd. | Malignant Neoplasms, Metastatic Cancer | 07/23 | 07/23 | | |
| Recruiting | 1 | 556 | RoW | IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 06/25 | 12/26 | | |
NCT05940116: A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 322 | RoW | HS-20117, PM1080 | Hansoh BioMedical R&D Company | Non-Small Cell Lung Cancer, Solid Tumor | 07/25 | 07/27 | | |
| Yang, Yang |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
NCT05043688: Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. |
|
|
| Recruiting | 3 | 426 | RoW | Camrelizumab, radiotherapy | Zhigang Li, Jiangsu HengRui Medicine Co., Ltd. | Resectable Esophageal Squamous Cell Carcinoma | 12/28 | 12/30 | | |
NCT05250843: TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC |
|
|
| Recruiting | 2/3 | 90 | RoW | TACE/HAIC, Lenvatinib, Sintilimab, liver resection | Third Affiliated Hospital, Sun Yat-Sen University | Hepatocellular Carcinoma | 12/23 | 12/24 | | |
NCT06272214: Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy |
|
|
| Recruiting | 2 | 146 | RoW | Adjuvant radiotherapy, Observation | Zhejiang Cancer Hospital | Adjuvant Radiotherapy | 03/27 | 03/29 | | |
NCT06413342: Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 191 | RoW | Sintilimab | Zhejiang Cancer Hospital | Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy, Elderly Patients | 06/26 | 06/28 | | |
IIT-2024-238, NCT06509568: Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） |
|
|
| Recruiting | 2 | 92 | RoW | Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy | Zhejiang Cancer Hospital | Esophageal Squamous Cell Carcinoma | 08/25 | 08/26 | | |
NCT05738057: Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 22 | RoW | Camrelizumab, Gemcitabine Injection, Cisplatin injection, Cisplatin-Eluting Beads, D-TACE | Hua Li | Unresectable Intrahepatic Cholangiocarcinoma | 03/25 | 03/26 | | |
NCT05417321: A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 80 | US, RoW | HB0036, Anti-PD-L1 and anti-TIGIT bifunctional molecule | Shanghai Huaota Biopharmaceutical Co., Ltd. | Advanced Solid Tumor, NSCLC | 08/25 | 08/25 | | |
NCT05940610: The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure |
|
|
| Withdrawn | 1/2 | 20 | RoW | MSC-EVs | Third Affiliated Hospital, Sun Yat-Sen University | Acute-On-Chronic Liver Failure, Acute Liver Failure | 09/24 | 10/25 | | |
NCT05881668: MSC-EV in Acute-on-Chronic Liver Failure After Liver Transplantation |
|
|
| Withdrawn | 1 | 30 | RoW | MSC-EV | Third Affiliated Hospital, Sun Yat-Sen University | Liver Failure, Acute on Chronic | 09/24 | 04/25 | | |
Neo-DRATEC, NCT03381651: Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma |
|
|
| Completed | N/A | 147 | RoW | Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation, Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation | Zhejiang Cancer Hospital | Esophageal Carcinoma, Neoadjuvant Chemoradiotherapy, Surgery | 02/21 | 02/23 | | |
| Recruiting | N/A | 300 | US | T'ai Chi and Qigong Rehabilitation, Usual care | New York Presbyterian Hospital, Center for Taiji and Qigong Studies & Wa-Qi.com | Low Back Pain | 06/23 | 06/23 | | |
NCT04707053: Data Collection and Analysis in Brainstem Surgeries |
|
|
| Recruiting | N/A | 150 | Europe | | Cantonal Hospital of St. Gallen | Brainstem Lesion, Surgery, Intraoperative Neurophysiologic Monitoring | 12/23 | 12/25 | | |
| Recruiting | N/A | 1000 | RoW | internet plus model, control | Guizhou Provincial People's Hospital | Neonatal Jaundice | 10/24 | 05/25 | | |
UTTS, NCT06743477: A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme |
|
|
| Not yet recruiting | N/A | 5 | RoW | Supergraft | Hu Peng | Stem Cell Transplantation | 12/26 | 12/26 | | |
NCT05707520: Long-term Benefit of MPA in Liver Transplantation |
|
|
| Recruiting | N/A | 500 | RoW | enteric-coated mycophenolate (MPAs), None MPA | Third Affiliated Hospital, Sun Yat-Sen University, Shulan (Hangzhou) Hospital, RenJi Hospital, The First Affiliated Hospital of Zhengzhou University, Beijing YouAn Hospital, Huashan Hospital, The Third Xiangya Hospital of Central South University, West China Hospital, Hebei Medical University Third Hospital, People's Hospital of Guangxi, Beijing Friendship Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Liver Transplant Rejection, Immunosuppressant Adverse Reaction | 06/23 | 09/23 | | |
| Zhou, Likun |
NCT03366883: Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC |
|
|
| Not yet recruiting | 3 | 420 | RoW | Paclitaxel, Cisplatin Plus 5-FU (TCF), radiochemotherapy | Tianjin Medical University Cancer Institute and Hospital, Shanghai Chest Hospital, Henan Cancer Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University | Esophageal Cancer Stage IIB, Esophageal Cancer Stage III | 02/18 | 12/22 | | |
| Li, Hongli |
NCT03366883: Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC |
|
|
| Not yet recruiting | 3 | 420 | RoW | Paclitaxel, Cisplatin Plus 5-FU (TCF), radiochemotherapy | Tianjin Medical University Cancer Institute and Hospital, Shanghai Chest Hospital, Henan Cancer Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University | Esophageal Cancer Stage IIB, Esophageal Cancer Stage III | 02/18 | 12/22 | | |
NCT04354662: Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer |
|
|
| Recruiting | 2 | 35 | RoW | Toripalimab, JS001, Docetaxel, Fluorouracil, Leucovorin, Oxaliplatin | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 03/22 | 06/24 | | |
NCT05035381: PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 10 | RoW | Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen, Bevacizumab, Irinotecan, Fluorouracil, Leucovorin | Tianjin Medical University Cancer Institute and Hospital | MSI-H Advanced Colorectal Cancer | 12/22 | 12/22 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 64 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gastroesophageal Adenocarcinoma | 09/26 | 09/27 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
| Recruiting | 1/2 | 103 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Biliary Tract Cancer | 05/25 | 12/25 | | |
| Recruiting | 1/2 | 364 | RoW | SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies | Jiangsu HengRui Medicine Co., Ltd. | HER2-expressing Advanced Solid Tumors | 11/26 | 12/26 | | |
| Deng, Ting |
NCT03366883: Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC |
|
|
| Not yet recruiting | 3 | 420 | RoW | Paclitaxel, Cisplatin Plus 5-FU (TCF), radiochemotherapy | Tianjin Medical University Cancer Institute and Hospital, Shanghai Chest Hospital, Henan Cancer Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University | Esophageal Cancer Stage IIB, Esophageal Cancer Stage III | 02/18 | 12/22 | | |
NCT04291248: A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor |
|
|
| Not yet recruiting | 2 | 138 | RoW | AK105, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | MSI-H or dMMR Advanced Solid Tumors | 12/22 | 12/22 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
NCT06383559: Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients |
|
|
| Recruiting | 2 | 39 | RoW | Lenvatinib and Sintilimab | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 07/26 | 09/26 | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
NCT06102746: Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma |
|
|
| Recruiting | 2 | 20 | RoW | Sintilimab，Surufatinib | Tianjin Medical University Cancer Institute and Hospital | Gastric Neuroendocrine Carcinoma | 04/26 | 04/26 | | |
NCT06102785: Fruquintinib Combined With TAS102 for Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Fruquintinib, TAS102 | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 10/26 | 10/26 | | |
NCT06102772: Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Adebrelimab，Fruquintinib | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 10/26 | 10/26 | | |
NCT06102759: Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed |
|
|
| Recruiting | 2 | 30 | RoW | Adebrelimab，Fruquintinib | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 10/26 | 10/26 | | |
NCT06464055: A Study of GQ1010 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 220 | RoW | Dose Escalation, Dose Expansion1, Dose Expansion2, phase II | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Advanced Malignant Solid Tumors | 05/28 | 12/28 | | |
| Recruiting | 1 | 150 | RoW | GQ1005 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | HER2 Expressing or Mutated Advanced Malignant Solid Tumors | 12/24 | 07/25 | | |
NCT06484790: NW-301 TCR-T in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 9 | RoW | NW-301V, NW-301D | Ting Deng, Neowise Biotechnology | Tumor, Solid | 04/26 | 04/27 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
| Recruiting | 1 | 50 | RoW | TR128 | Tarapeutics Science Inc. | Advanced Solid Tumor | 08/25 | 12/25 | | |
| Recruiting | N/A | 190 | RoW | | Peking University Cancer Hospital & Institute | DMMR Cancer, MSI-H, Solid Tumor | 02/26 | 02/26 | | |
| Liu, Rui |
PEACE, NCT06139692: Comparison of Perioperative Conscious Sedation During Endovascular Thrombectomy in Acute Ischemic Stroke |
|
|
| Recruiting | 4 | 810 | RoW | Dexmedetomidine, Midazolam | Jinling Hospital, China | Acute Ischemic Stroke | 11/25 | 02/26 | | |
NCT05035147: Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer |
|
|
| Recruiting | 4 | 934 | RoW | albumin-bound paclitaxel, gemcitabine | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 04/26 | 12/26 | | |
NCT03366883: Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC |
|
|
| Not yet recruiting | 3 | 420 | RoW | Paclitaxel, Cisplatin Plus 5-FU (TCF), radiochemotherapy | Tianjin Medical University Cancer Institute and Hospital, Shanghai Chest Hospital, Henan Cancer Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University | Esophageal Cancer Stage IIB, Esophageal Cancer Stage III | 02/18 | 12/22 | | |
NCT05092841: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A |
|
|
| Completed | 3 | 176 | RoW | PXT3003, (RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination, PXT3003 placebo, liquid oral solution | Tasly GeneNet Pharmaceuticals Co., Ltd | Charcot-Marie-Tooth Type 1A | 03/24 | 03/24 | | |
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC). |
|
|
| Completed | 3 | 298 | Europe, Canada, US, RoW | NovoTTF-200M device, Best Standard of Care | NovoCure GmbH | Brain Metastases from Non-small Cell Lung Cancer (NSCLC) | 11/24 | 11/24 | | |
| Recruiting | 3 | 248 | RoW | pimavanserin tartrate, placebo | Tasly Pharmaceutical Group Co., Ltd | Parkinson's Disease Psychosis | 06/25 | 01/26 | | |
Regosinti, NCT04745130: Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 90 | RoW | Sintilimab，regofinib，cetuximab, KRAS BRAF mutant Sintilimab + regafinil | Tianjin Medical University Cancer Institute and Hospital | Sintilimab, Cetuximab, Regorafenib,Combine,mCRC | 02/23 | 01/24 | | |
